Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

被引：0
|
作者：
Sabrina Wiebe
David Schnell
Raimund Külzer
Dietmar Gansser
Anne Weber
Gudrun Wallenstein
Atef Halabi
Anja Conrad
Sven Wind
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Datamap GmbH,undefined
[3] Clinical Research Services (CRS) Kiel GmbH,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2017年 / 42卷
关键词：
Renal Impairment; Epidermal Growth Factor Receptor Mutation; Plasma Protein Binding; Severe Renal Impairment; Advanced Solid Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 469
页数：8
相关论文
共 50 条
  • [11] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Wason, Suman
    Mount, David
    Faulkner, Robert
    CLINICAL DRUG INVESTIGATION, 2014, 34 (12) : 845 - 855
  • [12] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Suman Wason
    David Mount
    Robert Faulkner
    Clinical Drug Investigation, 2014, 34 : 845 - 855
  • [13] Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study
    Chattopadhyay, Niladri
    Riecke, Kai
    Ligges, Sandra
    Zimmermann, Torsten
    Halabi, Atef
    Schultze-Mosgau, Marcus-Hillert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 2011 - 2021
  • [14] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
    Kenneth Duchin
    Giorgio Senaldi
    Vance Warren
    Thomas Marbury
    Kenneth Lasseter
    Hamim Zahir
    Clinical Drug Investigation, 2018, 38 : 1001 - 1009
  • [15] Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
    Peveling-Oberhag, Jan
    Zeuzem, Stefan
    Yong, Wei Peng
    Kunz, Tiffany
    Paquet, Thierry
    Bouillaud, Emmanuel
    Urva, Shweta
    Anak, Oezlem
    Sellami, Dalila
    Kobalava, Zhanna
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 215 - 225
  • [16] Effects of Hepatic Impairment on the Pharmacokinetics of Nilotinib: An Open-Label, Single-Dose, Parallel-Group Study
    Yin, Ophelia Q. P.
    Gallagher, Neil
    Tanaka, Chiaki
    Fisher, Deirdre
    Sethuraman, Venkat
    Zhou, Wei
    Lin, Tsu-Han
    Heuman, Douglas
    Schran, Horst
    CLINICAL THERAPEUTICS, 2009, 31 : 2459 - 2469
  • [17] EFFECT OF HEPATIC IMPAIRMENT ON COBIMETINIB PHARMACOKINETICS: AN OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY.
    Templeton, I.
    Kshirsagar, S.
    Deng, Y.
    Choong, N.
    Chang, I.
    Georgescu, I.
    Musib, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S102 - S102
  • [18] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
    Duchin, Kenneth
    Senaldi, Giorgio
    Warren, Vance
    Marbury, Thomas
    Lasseter, Kenneth
    Zahir, Hamim
    CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1001 - 1009
  • [19] A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Marbury, Thomas
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (09): : 1713 - 1724
  • [20] A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
    Ou, Ying C.
    Preston, Richard A.
    Marbury, Thomas C.
    Tang, Zhiyu
    Novotny, William
    Tawashi, Manal
    Li, Ta-Kai
    Sahasranaman, Srikumar
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1355 - 1363
12345